SCHMC

Bortezomib Induced Tumor Lysis Syndrome in Multiple Myeloma

Metadata Downloads
Abstract
The tumor lysis syndrome (TLS) commonly occurs in the lymphoproliferative disorder, either spontaneously or in response to therapy. TLS is uncommon in multiple myeloma. However, with the use of bortezomib in the treatment of multiple myeloma, cases of TLS have been reported. We report here threepatients who presented with TLS after the administration of bortezomib. Two of them presented mild symptoms and recovered with hydration only. However, death of the other patient was associated with TLS. We should monitor patients who had high tumor burden, especially in early phase of bortezomib therapy and appropriate prophylaxis for high risk patient is also needed.
All Author(s)
S. Yu ; S. W. Ryu ; K. H. Kim ; S. H. Kim ; N. S. Lee ; S. K. Park ; J. H. Won
Intsitutional Author(s)
유시내
Issued Date
2013
Type
Article
Keyword
BortezomibMultiple myelomaTumor lysis syndrome
ISSN
2233-4289
Citation Title
Soonchunhyang Medical Science
Citation Volume
19
Citation Number
1
Citation Start Page
31
Citation End Page
33
Language(ISO)
eng
DOI
10.15746/sms.13.008
URI
http://schca-ir.schmc.ac.kr/handle/2022.oak/1038
Appears in Collections:
감염내과 > 1. Journal Papers
Authorize & License
  • Authorize공개
Files in This Item:

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.